单吸入器三联制剂在未控制哮喘中的应用进展  

Application progress of single inhaler triple therapy in uncontrolled asthma

作　　者：刘颖[1] 蒋毅[2] 铁增华 岳倩如 Liu Ying;Jiang Yi;Tie Zenghua;Yue Qianru(The First Clinical Medical College,Shanxi Medical University,Taiyuan 030001,China;NHC Key Laboratory of Pneumoconiosis,Shanxi Province Key Laboratory of Respiratory Diseases,Department of Pulmonary and Critical Care Medicine,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,山西太原030001 [2]国家卫生健康委尘肺病重点实验室,呼吸疾病山西省重点实验室,山西医科大学第一医院呼吸与危重症医学科,山西太原030001

出　　处：《实用药物与临床》2023年第10期947-950,共4页Practical Pharmacy and Clinical Remedies

摘　　要：哮喘是一种以慢性气道炎症反应为特征的异质性疾病。目前仍有部分患者即使规律治疗,哮喘症状仍未得到良好控制,全球哮喘防治倡议(GINA)建议可将长效胆碱能受体拮抗剂(LAMA)作为吸入性糖皮质激素/长效β2受体激动剂(ICS/LABA)的附加治疗。目前,已经有3种单吸入器三联制剂用于未控制哮喘患者的临床研究,本文对其在未控制哮喘中的应用进展进行综述。Asthma is a heterogeneous disease characterized by chronic airway inflammation.At present,there are still some patients whose asthma symptoms have not been well controlled even if they are treated regularly.GINA proposes that long-acting cholinergic receptor antagonist(LAMA)could be used as the additional treatment to inhaled corticosteroids/long-actingβ2 adrenergic bronchodilators(ICS/LABA).At present,there are three kinds of clinical studies of single inhaler triple therapy for uncontrolled asthma.This article reviews the progress of its application in uncontrolled asthma.

关 键 词：未控制哮喘 临床疗效 安全性 单吸入器三联制剂 

分 类 号：R562.25[医药卫生—呼吸系统]